{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:28:28Z","timestamp":1790155708644,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ymgme.2012.12.005","type":"journal-article","created":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T16:06:35Z","timestamp":1356710795000},"page":"132-137","source":"Crossref","is-referenced-by-count":33,"title":["A revised home treatment algorithm for Fabry disease: Influence of antibody formation"],"prefix":"10.1016","volume":"108","author":[{"given":"B.E.","family":"Smid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Hoogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Wijburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2012.12.005_bb0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0010","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V82.4.1107.1107","article-title":"Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients","volume":"82","author":"Zimran","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.ymgme.2012.12.005_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/ndt\/gfi221","article-title":"Home treatment for Fabry disease: practice guidelines based on 3years experience in The Netherlands","volume":"21","author":"Linthorst","year":"2006","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ymgme.2010.06.011","article-title":"Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II \u2014 data from the Hunter Outcome Survey","volume":"101","author":"Burton","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10545-007-0686-8","article-title":"Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe","volume":"30","author":"Cox-Brinkman","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12968\/bjon.2006.15.6.20681","article-title":"Intravenous enzyme replacement therapy: better in home or hospital?","volume":"15","author":"Milligan","year":"2006","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0035","doi-asserted-by":"crossref","first-page":"892","DOI":"10.12968\/bjon.2010.19.14.49047","article-title":"Intravenous enzyme replacement therapy: hospital vs home","volume":"19","author":"Parini","year":"2010","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0040","doi-asserted-by":"crossref","DOI":"10.12968\/bjon.2007.16.22.27768","article-title":"Mehta A: home therapy for lysosomal storage disorders","volume":"16","author":"Hughes","year":"2007","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0045","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0050","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","article-title":"Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme","volume":"10","author":"Bodensteiner","year":"2008","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0065","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jpeds.2007.09.007","article-title":"Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease","volume":"152","author":"Wraith","year":"2008","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0075","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg\/kg","volume":"2","author":"Vedder","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2012.12.005_bb0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-6-69","article-title":"Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients","volume":"6","author":"Smid","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0085","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ymgme.2008.03.003","article-title":"Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3","volume":"94","author":"Vedder","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0090","unstructured":"FIELD: NCT00701415. 2012. Ref Type: Internet Communication."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0095","doi-asserted-by":"crossref","first-page":"653","DOI":"10.12968\/bjon.2008.17.10.29481","article-title":"Home-based infusion therapy for patients with Fabry disease","volume":"17","author":"Cousins","year":"2008","journal-title":"Br. J. Nurs."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2010.11.169","article-title":"Anti-alpha-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry registry","author":"Wilcox","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","article-title":"Long-term safety and efficacy of enzyme replacement therapy for Fabry disease","volume":"75","author":"Wilcox","year":"2004","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0110","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2362.2010.02458.x","article-title":"Modelling the resource implications of managing adults with Fabry disease in Italy","volume":"41","author":"Guest","year":"2011","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2012.12.005_bb0115","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1365-2362.2010.02363.x","article-title":"Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion","volume":"40","author":"Guest","year":"2010","journal-title":"Eur. J. Clin. Invest."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212007184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719212007184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,19]],"date-time":"2020-07-19T09:56:13Z","timestamp":1595152573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719212007184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S1096719212007184"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2012.12.005","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}